CSBR Stock Analysis: Buy, Sell, or Hold?
CSBR - Champions Oncology, Inc.
$4.96
-0.22 (-4.25%)
▼
5d:
-2.07%
30d:
-17.33%
90d:
-16.64%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Sep 21, 2026
27d
Get Alerted When CSBR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CSBR shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CSBR shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CSBR is currently trading at $4.96, which is considered oversold relative to its 30-day fair value range of $5.04 to $5.90. From a valuation perspective, the stock is trading at a discount (Forward PE: 49.6) compared to its historical average (57.0). Remarkably, the market is currently pricing in an annual earnings decline of 4.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CSBR is in a downtrend. The price is currently testing key support at $4.83. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: CSBR scores 99/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $12.00 (+141.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CSBR is in a downtrend. The price is currently testing key support at $4.83. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: CSBR scores 99/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $12.00 (+141.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.04 -
$5.90
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
85.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (99/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.2%)
- BULLISH: Trading 141.9% below Wall St target ($12.00)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.04 -
$5.90
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.83
Resistance Level
$5.39
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
49.60
Wall Street Target
$12.00
(+141.9%)
Revenue Growth (YoY)
12.0%
Earnings Growth (YoY)
-61.1%
Profit Margin
-2.0%
Valuation Discount vs History
-4.5% cheaper
PE vs Historical
49.6 vs 57.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.5%
(market-implied from PE analysis)
1-Year Target
$4.74
(-5%)
2-Year Target
$4.52
(-9%)
3-Year Target
$4.32
(-13%)
3-Yr Target (if PE normalizes)
(PE: 50→57)
$4.96
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 49.6, Growth: -16.7%)
$3.62
(+-27%)
Base:
(SPY PE: 20.1, Growth: -16.7%)
$1.46
(-71%)
Bear:
(PE: 17.1, Growth: -16.7%)
$1.24
(-75%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 49.6 to 57.0
Stabilization Target:
$5.70
(+14.9%)
PE Expansion Potential:
+14.9%
Share & Embed Analysis
Last updated: August 23, 2026 8:11 PM ET
Data refreshes hourly during market hours. Next update: 9:11 PM
Data refreshes hourly during market hours. Next update: 9:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CSBR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 50 HOLD |
|
SMMT
Summit Therapeutics PLC |
STRONG BUY
10 analysts |
$29 | 55 HOLD |
